a) | All women | Â | |
---|---|---|---|
Percent adherence during any of the visits 2- 24 weeks | ≤ 400 copies/ml | >400 copies/ml | Univariable odds ratio (CI 95%); p value |
100% (n = 28) | 27 (20%) | 1 (9%) | 1 |
Ever <100% (n = 119) | 109 (80%) | 10 (91%) | 2.5 (0.3-111.4); 0.69* |
>95% (n = 92) | 87 (64%) | 5 (45%) | 1 |
Ever <95% (n = 55) | 49 (36%) | 6 (55%) | 2.1 (0.5-9.3); 0.33* |
>90% (n = 105) | 99 (73%) | 6 (55%) | 1 |
Ever <90% (n = 42) | 37 (27%) | 5 (45%) | 2.2 (0.5-9.3); 0.30* |
>80% (n = 122) | 116 (85%) | 6 (55%) | 1 |
Ever <80% (n = 25) | 20 (15%) | 5 (45%) | 4.8 (1.0-20.8); 0.02* |
>70% (n = 137) | 129 (95%) | 8 (73%) | 1 |
Ever <70% (n = 10) | 7 (5%) | 3 (27%) | 6.9 (1.0-37.7); 0.03* |
b) | Exposed to sdNVP | Â | |
Percent adherence during any of the visits 2- 24 weeks | ≤ 400 copies/ml | > 400 copies/ml | Univariable odds ratio (CI 95%); p value |
100% (n = 18) | 18 (21%) | 0 | 1 |
Ever <100% (n = 72) | 67 (79%) | 5 (100%) | NA: 0.58* |
>95% (n = 62) | 61 (72%) | 1 (20%) | 1 |
Ever <95% (n = 28) | 24 (28%) | 4 (80%) | 10.2 (0.9-508.5); 0.03* |
>90% (n = 69) | 68 (80%) | 1 (20%) | 1 |
Ever <90% (n = 21) | 17 (20%) | 4 (80%) | 16 (1.4-798.9); 0.01* |
>80% (n = 75) | 74 (87%) | 1 (20%) | 1 |
Ever <80% (n = 15) | 11 (13%) | 4 (80%) | 26.9 (2.2-1341.7); <0.01* |
>70% (n = 83) | 80 (94%) | 3 (60%) | 1 |
Ever <70% (n = 7) | 5 (6%) | 2 (40%) | 10.7 (0.7-112.3); 0.01* |
 | Not exposed to sdNVP |  | |
 | ≤ 400 copies/ml | > 400 copies/ml | Univariable odds ratio (CI 95%); p value |
100% (n = 10) | 9 (18%) | 1 (17%) | 1 |
Ever <100% (n = 47) | 42 (82%) | 5 (83%) | 1.1 (0.1-56.2); 1.00* |
>95% (n = 30) | 26 (51%) | 4 (67%) | 1 |
Ever <95% (n = 27) | 25 (49%) | 2 (33%) | 0.5 (0-4.1); 0.67* |
>90% (n = 36) | 31 (61%) | 5 (83%) | 1 |
Ever <90% (n = 21) | 20 (39%) | 1 (17%) | 0.3 (0-3.1); 0.40* |
>80% (n = 47) | 42 (82%) | 5 (83%) | 1 |
Ever <80% (n = 10) | 9 (18%) | 1 (17%) | 0.9 (0-10.0); 1.00* |
>70% (n = 54) | 49 (96%) | 5 (83%) | 1 |
Ever <70% (n = 3) | 2 (4%) | 1 (17%) | 4.9 (0.1-106.0); 0.29* |